CCEL - Cryo-Cell International, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
6.98
-0.02 (-0.29%)
As of 10:38AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close7.00
Open6.50
Bid0.00 x 0
Ask0.00 x 0
Day's Range6.35 - 6.99
52 Week Range5.50 - 9.30
Volume727
Avg. Volume1,488
Market Cap54.467M
Beta (3Y Monthly)0.10
PE Ratio (TTM)27.37
EPS (TTM)0.25
Earnings DateApr 11, 2019 - Apr 15, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.00
Trade prices are not sourced from all markets
  • GlobeNewswirelast month

    Cord Blood Banking Leader Cryo-Cell Reports Fiscal First Quarter 2019 Financial Results

    OLDSMAR, Fla., April 15, 2019 -- Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the “Company”), the world’s first private cord blood bank to separate and.

  • GlobeNewswire3 months ago

    Cryo-Cell Reports Financial Results for Fiscal Year Ended November 30, 2018

    Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for its fiscal year ended November 30, 2018. The revenues for fiscal 2018 consisted of $27.8 million in processing and storage fee revenue, $1.0 million in licensee income, $104,000 in product revenue and $296,000 in public banking revenue compared to $23.9 million in processing and storage fee revenue, $1.0 million in licensee income, $442,000 in product revenue and $0 in public banking revenue for fiscal 2017. Due to the acquisition of Cord:Use Cord Blood Bank, Inc. (“Cord:Use”), the Company now records public banking revenue which is generated from the sale of the donated cord blood units to the National Marrow Donor Program (“NMDP”), which distributes the cord blood units to transplant centers located in the United States and around the world.

  • We're sorry this is all we were able to find about this topic.